Denosin and Xyzal

ApprovedSmall molecule

Denosin and Xyzal is one of 19 small molecule programs targeting Chronic Idiopathic Urticaria. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Idiopathic UrticariaActive, not recruiting

Chronic Idiopathic UrticariaApproved

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Chronic Idiopathic Urticaria

#DrugCompanyPhaseTrials

Epidiolex

Zyrtec

2 3

Xolair

Roche

Phase 3

7 4

Benadryl

PParkedale

Phase 3

2 5

Bilaxten

MMenarini International Operations Luxembourg SA

Phase 3

1 6

Xyzal

CChattem

Phase 3

1 7

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

—8

Levocetirizine Dihydrochloride

UCB

Phase 3

1 9

Trexall

Alnylam Pharmaceuticals

Phase 2

1 10

Fasenra

AstraZeneca

Phase 2

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Idiopathic Urticaria1 trial

The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria

Unknown status·LLotus Pharmaceutical·Phase 4·NCT00346606·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Denosin and Xyzal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Denosin and Xyzal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Denosin and Xyzal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lotus Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: LLotus Pharmaceutical

Denosin and Xyzal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Idiopathic Urticaria1 trial

References

Drug Info

Quick Facts

Related News